- Home
- PRCT
as 02-21-2025 4:00pm EST
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.
Upcoming Earnings Alert:
Get ready for potential market movements as PROCEPT BioRobotics Corporation PRCT prepares to release earnings report on 25 Feb 2025.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 4.7B | IPO Year: | 2021 |
| Target Price: | $97.86 | AVG Volume (30 days): | 764.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $45.20 - $103.81 | Next Earning Date: | 02-25-2025 |
| Revenue: | $199,843,000 | Revenue Growth: | 71.71% |
| Revenue Growth (this year): | 67.07% | Revenue Growth (next year): | 40.64% |
Stock Insider Trading Activity of PROCEPT BioRobotics Corporation (PRCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nouri Alaleh | PRCT | EVP, CLO, CORP. SEC. | Dec 4 '24 | Sell | $97.00 | 28,092 | $2,728,573.90 | 76,777 | |
| Zadno Reza | PRCT | President, CEO | Dec 4 '24 | Sell | $97.57 | 26,423 | $2,568,844.46 | 160,123 | |
| Zadno Reza | PRCT | President, CEO | Nov 27 '24 | Sell | $98.61 | 26,420 | $2,584,637.91 | 160,123 |
Latest PROCEPT BioRobotics Corporation News
PRCT Breaking Stock News: Dive into PRCT Ticker-Specific Updates for Smart Investing
Insider Monkey
9 days ago
Procept BioRobotics Corp. (PRCT): Among the Best Mid-Cap Growth Stocks to Buy According to Analysts
GlobeNewswire
15 days ago
PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference
Simply Wall St.
a month ago
PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) institutional investors lost 12% over the past week but have profited from longer-term gains
Zacks
a month ago
PROCEPT BioRobotics (PRCT) Upgraded to Strong Buy: Here's What You Should Know
MT Newswires
a month ago
Procept BioRobotics' Addressable Market Estimate Challenged by Spruce Point Capital
TipRanks
2 months ago
Morgan Stanley Sees Potential Growth in These 2 Surgical Robotic Stocks
MT Newswires
3 months ago
Procept Biorobotics Insider Sold Shares Worth $2,728,574, According to a Recent SEC Filing
MT Newswires
3 months ago
Procept Biorobotics Insider Sold Shares Worth $2,584,638, According to a Recent SEC Filing
Compare PRCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRCT PROCEPT BioRobotics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.